BioCentury
ARTICLE | Clinical News

ISIS 2302 antisense inhibitor of intercellular adhesion molecule 1: Phase IIa trial

December 9, 1996 8:00 AM UTC

Isis Pharmaceuticals (ISIP), Carlsbad, Calif. Product: ISIS 2302 antisense inhibitor of intercellular adhesion molecule 1 ( ICAM-1) Indication: Crohn's disease Status: ISIP completed the first Phase ...